Clinical trials: Renal Transplant Infection
Urinary Tract Infection, Asymptomatic Bacteriuria
Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients
A clinical controlled, randomized and double blind trial that included adult patients (≥18 years) receiving kidney transplantation (KT) at the INCMNSZ.
- Trial name
- PERIFOS (NCT03235947)
- Testing
- Fosfomycin disodium, Trimethoprim / Sulfamethoxazole
- Where
- Mexico
- Volunteers
- 82 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Hiv, Kidney Transplant
Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
The purpose of this proof of concept, pilot study is to determine whether the unique combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and the mammalian target of rapamycin (mTOR) inhibitor…
- Conditions
- Hiv, Kidney Transplant, HIV Reservoir, CCR5
- Trial name
- NCT02990312
- Testing
- Sirolimus + Maraviroc
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Aspergillosis
Surveillance of Fungal Infections During Construction Activity
Fungal infections in immunocompromised patients occuring during construction activities in hospitals have repeatedly been reported.
- Trial name
- NCT00473252
- Where
- Switzerland
- Volunteers
- 340 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cytomegalovirus Infection
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring…
- Trial name
- LUCY-1 (NCT06334497)
- Testing
- Letermovir, Valganciclovir
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
End Stage Renal Disease, Chronic Hepatitis c
Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access
This is a single patient, single center study evaluating if administration of pan-genotypic DAA therapy on day 3 (+/- 2 days) post-kidney transplant prevents the transmission of hepatitis C virus infection from an HCV-positive…
- Trial name
- NCT04614142
- Testing
- Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
This phase I trial studies how well tacrolimus, nivolumab, and ipilimumab work in treating kidney transplant recipients with cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT03816332
- Testing
- Ipilimumab, Nivolumab, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
COVID-19, Renal Transplant Infection
COVID-19 Infection
Post-transplant patients with COVID-19 infection who attended Shenzhen No. 3 Hospital from December 2022 to February 2023, and enrolled the general population with COVID-19 infection who were hospitalized during the same period…
- Trial name
- NCT05926076
- Testing
- Treatment plan
- Where
- China
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Tianjin First Central Hospital
End-Stage Renal Disease, Kidney Failure
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.
- Conditions
- End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury
- Trial name
- NCT01756508
- Testing
- eculizumab
- Where
- Russia
- Volunteers
- 57 people
- Sponsor
- Russian Academy of Medical Sciences
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
Sepsis and Septic Shock, Acute Respiratory Failure
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022.
- Conditions
- Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients, Immunosuppressive Agents
- Trial name
- REDIS (NCT06881927)
- Testing
- Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression
- Where
- France
- Volunteers
- 212 people
- Sponsor
- University Hospital, Strasbourg, France
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
Covid19
Comorbidities and Risk Score in COVID-19 Patients
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included.
- Trial name
- Comorbidities (NCT04670094)
- Where
- 5 sites in Italy
- Volunteers
- 4,555 people
- Sponsor
- University of Milano Bicocca
Urinary Tract Infections, Transplant-Related Disorder
Treatment Chronic UTI Post Kidney Transplant
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E…
- Trial name
- NCT05967130
- Testing
- Phage
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
Covid19, Kidney Transplantation
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general…
- Trial name
- COVATRANS (NCT04828460)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Strasbourg, France
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection…
- Trial name
- EarlyFMT (NCT04885946)
- Testing
- Fecal microbiota transplantion (FMT)
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Christian Lodberg Hvas
SARS-CoV-2 Infection, Active Immunization
Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff
To investigate short- (3 and 8 weeks) and long-term (6, 9, 12, and 18 months) immune protection or response at the humoral and cellular levels before and after SARS-CoV-2 infection or vaccination in patients with moderately…
- Conditions
- SARS-CoV-2 Infection, Active Immunization, Immune Response, Immunosuppression
- Trial name
- DIA-Vacc (NCT04799808)
- Where
- Germany
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden